1. Home
  2. SKYE vs NATR Comparison

SKYE vs NATR Comparison

Compare SKYE & NATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • NATR
  • Stock Information
  • Founded
  • SKYE 2012
  • NATR 1972
  • Country
  • SKYE United States
  • NATR United States
  • Employees
  • SKYE N/A
  • NATR N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • NATR Biotechnology: Pharmaceutical Preparations
  • Sector
  • SKYE Health Care
  • NATR Health Care
  • Exchange
  • SKYE Nasdaq
  • NATR Nasdaq
  • Market Cap
  • SKYE 176.8M
  • NATR 285.4M
  • IPO Year
  • SKYE N/A
  • NATR N/A
  • Fundamental
  • Price
  • SKYE $5.89
  • NATR $15.55
  • Analyst Decision
  • SKYE Strong Buy
  • NATR Strong Buy
  • Analyst Count
  • SKYE 4
  • NATR 1
  • Target Price
  • SKYE $19.25
  • NATR $24.00
  • AVG Volume (30 Days)
  • SKYE 384.5K
  • NATR 64.3K
  • Earning Date
  • SKYE 01-01-0001
  • NATR 08-07-2024
  • Dividend Yield
  • SKYE N/A
  • NATR N/A
  • EPS Growth
  • SKYE N/A
  • NATR 400.00
  • EPS
  • SKYE N/A
  • NATR 0.85
  • Revenue
  • SKYE N/A
  • NATR $447,679,000.00
  • Revenue This Year
  • SKYE N/A
  • NATR $4.39
  • Revenue Next Year
  • SKYE N/A
  • NATR $6.00
  • P/E Ratio
  • SKYE N/A
  • NATR $18.38
  • Revenue Growth
  • SKYE N/A
  • NATR 6.58
  • 52 Week Low
  • SKYE $1.44
  • NATR $13.36
  • 52 Week High
  • SKYE $19.41
  • NATR $21.72
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 34.36
  • NATR 53.42
  • Support Level
  • SKYE $5.95
  • NATR $14.80
  • Resistance Level
  • SKYE $6.83
  • NATR $16.36
  • Average True Range (ATR)
  • SKYE 0.82
  • NATR 0.51
  • MACD
  • SKYE 0.09
  • NATR 0.15
  • Stochastic Oscillator
  • SKYE 21.26
  • NATR 61.61

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About NATR Nature's Sunshine Products Inc.

Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.

Share on Social Networks: